Please login to the form below

Ionis

This page shows the latest Ionis news and features for those working in and with pharma, biotech and healthcare.

Alnylam gets EU nod for Onpattro amid pricing backlash

Ionis and Akcea secured EMA approval last month for their antisense candidate Tegsedi (inotersen), but are still in the process of negotiating price and reimbursement with individual EU countries, while ... Neither Tegsedi or Vyndaqel are approved yet in

Latest news

ICER says Alnylam’s Onpattro should cost 90%-95% less

In draft guidance, the Institute for Clinical and Economic Review (ICER) says that RNA interference drug Onpattro (patisiran) – and Akcea/Ionis’antisense candidate Tegsedi (inotersen) which is due for an FDA
Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding

Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding. ... The news sent Akcea’s share price crashing, and spoils the recent good news of Ionis’first ever drug approval, Tegsedi, gaining clearance from the EU in July.
Alnylam claims first RNAi approval from FDA for patisiran

Patisiran is the first FDA-approved drug for hATTR amyloidosis in the US, but will only claim third place in Europe after Akcea/Ionis’antisense oligonucleotide rival Tegsedi (inotersen), which was
Ionis and Roche gain PRIME status for Huntingdon’s disease candidate

The announcement adds to the momentum behind Ionis, which has just gained its first ever drug approval - also in Europe. ... C. Frank Bennett, senior vice president of research and franchise leader for the neurological programmes at Ionis.
Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

It’s the second drug for hATTR amyloidosis to clear the CHMP after Akcea/Ionis’antisense oligonucleotide Tegsedi (inotersen), which was given a positive opinion in May and approved by the

More from news
Approximately 10 fully matching, plus 22 partially matching documents found.

Latest Intelligence

The European Medicines Agency: PRIME’d for access?

Since March 2018 Roche, with Ionis, have added another PRIME drug to their portfolio. ... RG6042 (formerly named IONIS-HTTRx) is in development for Huntington’s disease.
Deal Watch February 2017

Ionis has recently received a $75m milestone payment from Bayer having successfully completed a phase II study on IONIS-FXIRx in patients with end-stage renal disease on haemodialysis. ... As part of the agreement Ionis will also expand the collaboration
Deal Watch January 2017

As you sow, so shall you reap The use of options is remaining widespread as noted in the Novartis deal with Ionis and Akcea. ... 1, 700. Ionis | Akcea. Novartis. Exclusive option to licence. AKCEA-APOCIII-LRx for heart failure.
Deal Watch August 2016

95. Ionis (US). Biogen (US). Exercise option . Nusinersen, in phase III for treatment for spinal muscular atrophy.
Deal Watch May 2016

This month GSK elected not to currently proceed with its option to Ionis Pharmaceuticals' IONIS-TTRrx, which was about to enter into phase 3 clinical development. ... The knock on effect for Ionis shares was a dip by a significant 40%.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Medical Writers Required - Hertfordshire: Competitive

Healthcare PR Senior Account Manager: Salary TBC

Account Manager: Negotiable

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Account Director or Senior Account Director: Salary TBC

Graduate Scientific Editor: DOE

Senior Account Manager – Healthcare Advertising: Salary TBC

Senior Medical Writer: Salary is DOE

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Medical Writer, MedComms Agency: Salary TBC

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Sudler London - Senior Medical Writer: Competitive

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Systematic Review Lead- London: Negotiable

Sudler London - Account Director: Competitive

Market Access Consultant - Greater Manchester: Negotiable

Senior Writer, Healthcare Advertising, London: Excellent package

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....